MAZE (Maze Therapeutics) Issuance of Debt: $39.40 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAZE Maze Therapeutics Inc MAZE
16 GF Score
Price $27.53
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Issuance of Debt?

Maze Therapeutics MAZE +0.81% 16 Issuance of Debt is $39.40 Mil as of Jun. 2026. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Maze Therapeutics's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Maze Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $39.40 Mil.

Maze Therapeutics Issuance of Debt Related Terms

Maze Therapeutics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Issuance of Debt Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Issuance of Debt
0.00 16.18 24.48 0.00

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 39.40 0.00
MAZE
16GF Score
Maze Therapeutics Inc MAZE
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $39.40 Mil mean?
Maze Therapeutics (MAZE) has a Issuance of Debt of $39.40 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Issuance of Debt too high?
Maze Therapeutics' current Issuance of Debt is $39.40 Mil. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Issuance of Debt compare to NTLA and RXRX?
Maze Therapeutics' Issuance of Debt of $39.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Issuance of Debt is $39.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Issuance of Debt of $39.40 Mil. The current Issuance of Debt is $39.40 Mil. Maze Therapeutics' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Issuance of Debt is $39.40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score

Get the complete analysis for MAZE

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.53
Price